Earnings Call · Q3 FY2021·2021-11-02

Q3 21EPS +19.18%·Rev n/aQ2 21EPS -10.47%·Rev n/aQ1 21EPS +25.56%·Rev n/aQ4 20EPS -100.00%*·Rev n/a⚠ consensus missing

ADC Therapeutics SA ADCT

Amanda Hamilton — Investor Relations

Christopher Martin — Chief Executive Officer

Jennifer Herron — Head of U.S. ZYNLONTA Launch

Joe Camardo — Chief Medical Officer

Jennifer Creel — Chief Financial Officer

−7.4%1d on move date−7.8% vs SPY3d−6.3%5d−8.0%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ADCT calls or request research access.

More ADCT calls Browse calls Request research access